i have not reviewed the analyst report in detail, but one interesting question that arises (i think) is that the modelling essentially assumes that PRR "goes it alone" rather than doing a partnering/licencing deal.
Do you think that this is realistic?
It is at odds with the expectations of many on this forum that PRR may announce a deal of some sort with a major pharma company some time in the next few months.
Can PRR distribute the product widely without a partner?
Note that a partner would insist on a minimum of half of the revenues.
this is not downramping - it is a fair & honest question
i have not reviewed the analyst report in detail, but one...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
33.5¢ |
Change
0.015(4.69%) |
Mkt cap ! $486.6M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 33.5¢ | 32.0¢ | $1.303M | 3.974M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 29843 | 33.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.5¢ | 105523 | 4 |
View Market Depth
| Last trade - 16.10pm 25/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |